A Randomised, Double Blind, Three-Arm, Single Dose, Parallel Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar Drug), US Licenced Avastin® and EU Approved Avastin® in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors mAbxience
- 13 Aug 2019 Status changed from active, no longer recruiting to completed.
- 07 Mar 2019 Planned End Date changed from 1 Mar 2019 to 1 May 2019.
- 07 Mar 2019 Planned primary completion date changed from 1 Mar 2019 to 1 May 2019.